Search

Your search keyword '"Dioxolanes adverse effects"' showing total 79 results

Search Constraints

Start Over You searched for: Descriptor "Dioxolanes adverse effects" Remove constraint Descriptor: "Dioxolanes adverse effects" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
79 results on '"Dioxolanes adverse effects"'

Search Results

1. Adverse events associated with Stiripentol in children aged 0-17 years: An analysis of a real-world pharmacovigilance database.

2. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.

3. Stiripentol add-on therapy for drug-resistant focal epilepsy.

4. Antiepileptic Stiripentol May Influence Bones.

5. Stiripentol (Diacomit) for Dravet syndrome.

6. Starting stiripentol in adults with Dravet syndrome? Watch for ammonia and carnitine.

7. Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent.

8. Stiripentol add-on therapy for drug-resistant focal epilepsy.

9. Stiripentol: A Review in Dravet Syndrome.

10. Stiripentol for the treatment of seizures in Dravet syndrome.

11. Optimal patch test concentration for three widely used sensitizing fragrance substances without mandatory labelling in cosmetics.

12. Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome.

13. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy.

14. Stiripentol in the Management of Epilepsy.

15. Audit of use of stiripentol in adults with Dravet syndrome.

16. Stiripentol and vigabatrin current roles in the treatment of epilepsy.

17. Pharmacological considerations in the use of stiripentol for the treatment of epilepsy.

18. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy.

19. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.

20. β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.

21. Reassessment of stiripentol pharmacokinetics in healthy adult volunteers.

22. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence.

23. Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy.

24. Quantitation of tr-cinnamaldehyde, safrole and myristicin in cola-flavoured soft drinks to improve the assessment of their dietary exposure.

25. Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome).

26. Experimental and theoretical investigations of the autoxidation of geranial: a dioxolane hydroperoxide identified as a skin sensitizer.

27. Selective killing of cancer cells by a small molecule targeting the stress response to ROS.

28. Prulifloxacin ECG study.

29. Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study.

31. Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals.

32. Stiripentol open study in Japanese patients with Dravet syndrome.

33. Prulifloxacin as a trigger of myasthenia gravis.

34. Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.

35. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial.

36. Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis.

37. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.

38. Topiramate in the treatment of highly refractory patients with Dravet syndrome.

39. Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis.

40. Prulifloxacin: a new antibacterial fluoroquinolone.

41. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).

43. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients.

44. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer.

45. Stiripentol: new preparation. Severe myoclonic epilepsy of infancy: promising.

46. Stiripentol. A novel antiepileptic drug.

47. Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.

48. New nucleoside analogs in the treatment of hematological disorders.

49. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.

50. Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk.

Catalog

Books, media, physical & digital resources